However, PARP inhibitors are not effective in all patients with BRCA1/2 mutant prostate cancer, and the inactivation of DDR genes elicits genomic instability, leading to alterations in multiple genes and eventually to drug resistance [34]. This evidence concerns the gene PARP1 and prostate carcinoma.